"It feels like such a privilege to get to do this."
Where I see patients (3)
Selected research
-
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.
Blood advances
-
MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231.
Blood
-
A roadmap to establishing global oncology as a priority initiative within a National Cancer Institute-designated cancer center.
Journal of the National Cancer Institute
Clinical trials
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
To compare the rate of MRD >=0.01% at end of induction between experimental arm and control arm
Recruiting
More about this studyTagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Mali...
The incidence of dose limiting toxicity (DLT) will be measured at different dose levels.
Recruiting
More about this studyStudy of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
DFS is defined as the time from the date of tisagenlecleucel infusion to the date of the first documented morphological relapse, occurrence of secondary malignancy or death due to any cause.
Recruiting
More about this studyStudy Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants W...
Dose-limiting toxicity is defined as protocol-defined brexucabtagene autoleucel (KTE-X19)-related events with onset within the first 28 days following brexucabtagene autoleucel (KTE-X19) infusion.
Recruiting
More about this studyChemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
to assess overall response rate following chemoimmunotherapy induction therapy
Recruiting
More about this studyUse Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Ly...
Will be reported as number and percentage of patients meeting CR/CRi criteria at the end of 8 weeks of therapy
Recruiting
More about this studyLCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langer...
Stratum I, II, VI
Recruiting
More about this studyA Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractor...
Will be analyzed descriptively.
Recruiting
More about this studyContact me
Stress-free visits